Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
SAN DIEGO, March 01, 2018 -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will report financial results for the fourth quarter and full year 2017 as well as provide a corporate update at 4:30 p.m. EST on March 8, 2018.
The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 1898244. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days.
About Otonomy
Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for otology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus. For additional information please visit www.otonomy.com.
Contacts:
Media Inquiries
Canale Communications
Heidi Chokeir, Ph.D.
Senior Vice President
619.849.5377
[email protected]
Investor Inquiries
Westwicke Partners
Robert H. Uhl
Managing Director
858.356.5932
[email protected]
